Zydus Life Science Stock Screener | Share Price & Fundamental Analysis
ZYDUSLIFE
Pharmaceuticals
Screen Zydus Life Science share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹931.05
▲
9.10 (0.99%)
Share Price BSE
₹931.25
▲
9.45 (1.03%)
Market Cap
₹92,075.44 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.64
EPS (TTM)
₹44.97
Dividend Yield
1.20%
Debt to Equity
0.09
52W High
₹1049.95
52W Low
₹822.10
Operating Margin
31.00%
Profit Margin
20.16%
Revenue (TTM)
₹6,147.00
EBITDA
₹2,005.00
Net Income
₹1,239.00
Total Assets
₹37,202.00
Total Equity
₹26,358.00
Zydus Life Science Share Price History - Stock Screener Chart
Screen ZYDUSLIFE historical share price movements with interactive charts. Analyze price trends and patterns.
Zydus Life Science Company Profile - Fundamental Screener
Screen Zydus Life Science company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ZYDUSLIFE shares.
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Pankaj R Patel
ISIN
INE010B01027
Website
https://www.zyduscadila.com
Zydus Life Science Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ZYDUSLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 37,202 | 29,281 | 25,756 | 27,795 | 23,885 | 23,687 | 23,483 | 18,065 | 15,221 | 10,551 |
| Current Assets | 17,046 | 11,420 | 10,008 | 12,095 | 8,716 | 8,715 | 8,498 | 8,230 | 6,022 | 4,280 |
| Fixed Assets | 13,134 | 12,369 | 11,521 | 12,189 | 12,133 | 12,231 | 12,164 | 6,483 | 5,755 | 3,748 |
| Liabilities | ||||||||||
| Total Liabilities | 37,202 | 29,281 | 25,756 | 27,795 | 23,885 | 23,687 | 23,483 | 18,065 | 15,221 | 10,551 |
| Current Liabilities | 1,802 | 1,840 | 541 | 915 | 1,094 | 3,707 | 4,461 | 3,047 | 2,799 | 1,255 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 26,358 | 22,102 | 19,688 | 19,054 | 14,930 | 11,710 | 11,679 | 8,936 | 7,116 | 5,835 |
| Share Capital | 101 | 101 | 101 | 102 | 102 | 102 | 102 | 102 | 102 | 102 |
| Reserves & Surplus | 23,853 | 19,729 | 17,415 | 16,897 | 12,890 | 10,273 | 10,284 | 8,642 | 6,858 | 5,597 |
Screen ZYDUSLIFE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,147 | 6,622 | 6,371 | 5,181 | 5,182 | 6,110 | 5,526 | 4,403 | 4,313 | 5,089 | 4,890 | 4,199 | 3,993 | 3,989 | 3,821 |
| Expenses | 4,142 | 4,485 | 4,622 | 3,882 | 3,776 | 4,124 | 3,903 | 3,403 | 3,224 | 3,650 | 4,359 | 3,301 | 3,319 | 3,251 | 3,103 |
| EBITDA | 2,005 | 2,137 | 1,749 | 1,299 | 1,407 | 1,986 | 1,623 | 1,000 | 1,089 | 1,439 | 532 | 898 | 673 | 738 | 718 |
| Operating Profit % | 31.00% | 31.00% | 27.00% | 24.00% | 26.00% | 32.00% | 27.00% | 22.00% | 24.00% | 28.00% | 10.00% | 21.00% | 16.00% | 17.00% | 17.00% |
| Depreciation | 302 | 238 | 238 | 229 | 234 | 215 | 205 | 195 | 184 | 180 | 179 | 182 | 182 | 181 | 185 |
| Interest | 101 | 85 | 77 | 32 | 25 | 32 | 35 | 20 | 9 | 18 | 28 | 33 | 35 | 34 | 39 |
| Profit Before Tax | 1,687 | 1,921 | 1,672 | 1,184 | 1,271 | 1,900 | 1,550 | 947 | 1,006 | 1,328 | 484 | 781 | 648 | 673 | 558 |
| Tax | 449 | 400 | 428 | 158 | 351 | 417 | 304 | 157 | 203 | 195 | 125 | 149 | 122 | 96 | 105 |
| Net Profit | 1,239 | 1,521 | 1,244 | 1,026 | 920 | 1,483 | 1,246 | 790 | 803 | 1,134 | 358 | 631 | 526 | 576 | 453 |
| EPS | 12.51 | 14.58 | 11.64 | 10.17 | 9.06 | 14.11 | 11.69 | 7.80 | 7.91 | 10.74 | 2.93 | 6.15 | 5.15 | 5.06 | 3.88 |
Zydus Life Science Cash Flow Screener - Liquidity Fundamentals
Screen ZYDUSLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 6,777 | 3,196 | 2,689 | 2,105 | 3,294 | 2,932 | 1,282 | 919 | 1,312 | 1,894 |
| Investing Activities | -8,377 | -1,492 | 1,542 | -1,018 | -837 | -1,004 | -3,977 | -974 | -2,872 | -860 |
| Financing Activities | 2,014 | -1,779 | -4,400 | -868 | -2,548 | -1,528 | 1,885 | 52 | 2,316 | -935 |
| Net Cash Flow | 414 | -75 | -170 | 219 | -91 | 399 | -811 | -3 | 756 | 99 |
Screen ZYDUSLIFE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 74.99% | 74.99% | 74.99% | 74.98% | 74.98% | 74.98% | 74.98% | 74.98% |
| FII Holding | 7.34% | 7.13% | 7.32% | 7.53% | 7.52% | 5.59% | 5.72% | 0.00% |
| DII Holding | 10.86% | 11.13% | 11.01% | 10.65% | 10.65% | 12.64% | 12.63% | 12.79% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.49% | 5.46% | 5.41% | 5.47% | 5.48% | 5.37% | 5.29% | 5.60% |
| Other Holding | 1.32% | 1.28% | 1.28% | 1.36% | 1.37% | 1.43% | 1.38% | 6.63% |
| Shareholder Count | 396,105 | 386,127 | 371,619 | 365,356 | 370,863 | 336,309 | 294,324 | 306,495 |
Zydus Life Science Dividend Screener - Share Yield Analysis
Screen ZYDUSLIFE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹11.00 | 1.20% |
| 2024-March | ₹3.00 | 0.34% |
| 2023-March | ₹6.00 | 0.60% |
| 2022-March | ₹2.50 | 0.51% |
| 2021-March | ₹3.50 | 1.00% |
| 2020-March | ₹3.50 | 0.79% |
| 2019-March | ₹3.50 | 1.31% |
| 2018-March | ₹3.50 | 1.01% |
| 2017-March | ₹3.20 | 0.85% |
Zydus Life Science Index Membership - Market Screener Classification
Screen ZYDUSLIFE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Zydus Life Science Market Events Screener - Corporate Actions
Screen ZYDUSLIFE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.96% |
| 2025-08-12 | 2025-08-12 | Annual General Meeting | NA | 4.84% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -1.47% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 11.00 /share | 7.57% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 4.31% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | -2.16% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.36% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 26.80% |
| 2024-07-26 | 2024-07-26 | Dividend | ₹ 3.00 /share | 19.50% |
| 2024-02-23 | 2024-02-29 | Buyback | 1005 | -2.20% |
| 2023-07-28 | 2023-07-28 | Dividend | ₹ 6.00 /share | 25.19% |
| 2022-07-28 | 2022-07-29 | Dividend | ₹ 2.50 /share | 3.20% |
| 2021-07-28 | 2021-07-30 | Dividend | ₹ 3.50 /share | -8.95% |
Zydus Life Science Competitors Screener - Peer Comparison
Screen ZYDUSLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Zydus Life Science Company Announcements - News Screener
Screen ZYDUSLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-05 | Receipt Of Demand Order-In-Original From Assistant Commissioner Of State Tax Gujarat | View |
| 2026-01-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2026-01-01 | Intimation Of ESG Rating | View |
| 2026-01-01 | Closure of Trading Window | View |
| 2026-01-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-30 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2025-12-29 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-16 | Intimation Of ESG Rating | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-12 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |
| 2025-12-12 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2025-12-12 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |
| 2025-12-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-27 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-26 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-25 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-25 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |